Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

The Snippet: The Success of Cannabidiol

  • Home Blog The snippet the success of cannabidiol

The Snippet: The Success of Cannabidiol

Sep 30, 2016

GW Pharmaceuticals, a UK based company, believes in growing its own cannabis plants, search for its ingredients and then come up with medicines that help the company in taking one more step towards approval of Epidiolex, as seen in the announcement of positive phase 3 trial results earlier this week.

The drug is for the treatment of epilepsy including Dravet syndrome and lennox-Gastaut syndrome. Pateints who were on 20mg dosage of Epidiolex had 42% reduction in monthly seizures compared to 17% of control patients. The company is expecting to submit a new drug application with US FDA in the first half of 2017. On Monday, a sudden rise of more than 16% in the stocks of the company was noted.

The drug so far has got Orphan Drug Designation from FDA for the treatment of Dravet syndrome and lennox-Gastaut syndrome and Fast track designation for Dravet syndrome. The company has, thus, set a new standard in the market by announcing promising results of Epidiolex.

Downloads

Article in PDF

Recent Articles
  1. AstraZeneca’s Voydeya FDA Approval; Akebia’s Vafseo FDA Approval; Bristol Myers Squibb’s Phase II...
  2. FDA Breakthrough Device Designation to Pi-Cardia’s ShortCut; AbSolutions Med’s REBUILD Bioabsorba...
  3. Novartis Announces the Positive Results of Phase III NATALEE Trial Evaluating Kisqali; FDA Approv...
  4. Prosecutors rope Pfizer; Pharma groups to FDA; Regeneron simulates; Otsuka & Lundbeck revive...
  5. Notizia
pharma-news-for-applied-therapeutics-alnylam-rigel
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Grants Fast Track for Lin BioScience’s LBS-007; Alnylam’s AMVUTTRA sNDA Under Review; FDA Approves RAPIBLYK for Atrial Fibrillation; Applied Therapeutics Receives CRL for Govorestat in Galactosemia; R289 Gets Fast Track for Lower-Risk MDS.

pharma-news-for-Ractigen-intellia -bridgebio
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Grants Orphan Drug Designation for Ractigen’s RAG-21 in ALS; Intellia’s Nexiguran RMAT for ATTR Amyloidosis; FDA Approves Acoramidis for ATTR-CM; Jazz Wins FDA Approval for Ziihera in HER2-Positive Biliary Cancer; J&J Seeks FDA Approval for Subcutaneous TREMFYA in Colitis

pharma-news-for-regeneron-astrazeneca-syndax
Notizia - Recent Pharma, Healthcare and Biotech Happenings

FDA Approves PTC’s AADC Gene Therapy; DUPIXENT sBLA Acceptance for Urticaria; CHMP Recommends TAGRISSO for EGFR Lung Cancer; FDA Approves DANZITEN for CML; Syndax Wins FDA Approval for REVUFORJ in Acute Leukemia

Cannabidiol
Dravet syndrome
Epidiolex
FDA
GW Pharmaceuticals
Lennox Gastaut Syndrome
Orphan Drug
loader